Human Papillomavirus Lesions in 16 MS Patients Treated with Fingolimod: Outcomes and Vaccination - Sorbonne Université Access content directly
Journal Articles MULTIPLE SCLEROSIS JOURNAL Year : 2021

Human Papillomavirus Lesions in 16 MS Patients Treated with Fingolimod: Outcomes and Vaccination

Abstract

Few cases of human papillomavirus (HPV) diseases have been reported in multiple sclerosis (MS) patients treated with fingolimod. We describe a case series of 16 MS patients (11 women, 5 men) developing HPV lesions after the onset of fingolimod, without previous HPV history. Fingolimod had to be discontinued in six patients. Six patients received vaccination for HPV, with good tolerance. Our report highlights that systematic HPV screening and discussion about HPV vaccination before fingolimod onset are crucial. In case of occurrence of HPV lesions during fingolimod treatment, a comprehensive workup of HPV disease is necessary, with discussion of HPV vaccination to prevent secondary lesions. Prevalence studies of HPV lesions are needed in MS patients with the different disease-modifying therapies.
No file

Dates and versions

hal-03793498 , version 1 (01-10-2022)

Identifiers

Cite

Elsa Mhanna, Agathe Nouchi, Céline Louapre, Raphael de Paz, Olivier Heinzlef, et al.. Human Papillomavirus Lesions in 16 MS Patients Treated with Fingolimod: Outcomes and Vaccination. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (11), pp.1794--1798. ⟨10.1177/1352458521991433⟩. ⟨hal-03793498⟩
31 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More